Oppenheimer Reiterates Outperform Rating on Catalyst Pharmaceutical Partners (CPRX)

February 27, 2026 6:00 AM UTC Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $33.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login